{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:00:26Z","timestamp":1782450026298,"version":"3.54.5"},"reference-count":113,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is spreading worldwide with different clinical manifestations. Age and comorbidities may explain severity in critical cases and people living with human immunodeficiency virus (HIV) might be at particularly high risk for severe progression. Nonetheless, current data, although sometimes contradictory, do not confirm higher morbidity, risk of more severe COVID-19 or higher mortality in HIV-infected people with complete access to antiretroviral therapy (ART). A possible protective role of ART has been hypothesized to explain these observations. Anti-viral drugs used to treat HIV infection have been repurposed for COVID-19 treatment; this is also based on previous studies on severe acute respiratory syndrome virus (SARS-CoV) and Middle East respiratory syndrome virus (MERS-CoV). Among them, lopinavir\/ritonavir, an inhibitor of viral protease, was extensively used early in the pandemic but it was soon abandoned due to lack of effectiveness in clinical trials. However, remdesivir, a nucleotide analog that acts as reverse-transcriptase inhibitor, which was tested early during the pandemic because of its wide range of antiviral activity against several RNA viruses and its safety profile, is currently the only antiviral medication approved for COVID-19. Tenofovir, another nucleotide analog used extensively for HIV treatment and pre-exposure prophylaxis (PrEP), has also been hypothesized as effective in COVID-19. No data on tenofovir\u2019s efficacy in coronavirus infections other than COVID-19 are currently available, although information relating to SARS-CoV-2 infection is starting to come out. Here, we review the currently available evidence on tenofovir\u2019s efficacy against SARS-CoV-2.<\/jats:p>","DOI":"10.3390\/ph14050454","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T11:30:16Z","timestamp":1620732616000},"page":"454","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3902-3376","authenticated-orcid":false,"given":"Isabella","family":"Zanella","sequence":"first","affiliation":[{"name":"Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy"},{"name":"Clinical Chemistry Laboratory, Cytogenetics and Molecular Genetics Section, Diagnostic Department, ASST Spedali Civili di Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Zizioli","sequence":"additional","affiliation":[{"name":"Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9161-7804","authenticated-orcid":false,"given":"Francesco","family":"Castelli","sequence":"additional","affiliation":[{"name":"University Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1452-9100","authenticated-orcid":false,"given":"Eugenia","family":"Quiros-Roldan","sequence":"additional","affiliation":[{"name":"University Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,11]]},"reference":[{"key":"ref_1","unstructured":"(2021, April 12). Available online: https:\/\/www.who.int\/news-room\/q-a-detail\/coronavirus-disease-(covid-19)-vaccines."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11908-021-00752-3","article-title":"Status Report on COVID-19 Vaccines Development","volume":"23","author":"Kumar","year":"2021","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Golob, J.L., Lugogo, N., Lauring, A.S., and Lok, A.S. (2021). SARS-CoV-2 vaccines: A triumph of science and collaboration. JCI Insight, 2021.","DOI":"10.1172\/jci.insight.149187"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.3389\/fmicb.2020.01723","article-title":"Therapeutic Strategies against COVID-19 and Structural Characterization of SARS-CoV-2: A Review","volume":"11","author":"Jeong","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Romano, M., Ruggiero, A., Squeglia, F., Maga, G., and Berisio, R. (2020). A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping. Cells, 9.","DOI":"10.20944\/preprints202004.0510.v1"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"166725","DOI":"10.1016\/j.jmb.2020.11.024","article-title":"Structural insights into SARS-CoV-2 proteins","volume":"433","author":"Arya","year":"2021","journal-title":"J. Mol. Biol."},{"key":"ref_7","unstructured":"(2021, April 12). Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-covid-19."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bj.2020.11.005","article-title":"Lopinavir\/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment","volume":"44","author":"Magro","year":"2021","journal-title":"Biomed. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","article-title":"Treatment with Lopinavir\/Ritonavir or Interferon-\u03b21b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset","volume":"212","author":"Chan","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A Trial of Lopinavir\u2013Ritonavir in Adults Hospitalized with Severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"WHO Solidarity Trial Consortium (2021). Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results. N. Engl. J. Med., 384, 497\u2013511.","DOI":"10.1056\/NEJMoa2023184"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"RECOVERY Collaborative Group (2020). Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet, 396, 1345\u20131352.","DOI":"10.1016\/S0140-6736(20)32013-4"},{"key":"ref_13","unstructured":"(2021, April 12). Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-aids."},{"key":"ref_14","first-page":"68","article-title":"Early Insights into COVID-19 in Persons Living with HIV and Cardiovascular Manifestations","volume":"2","author":"Grant","year":"2020","journal-title":"J. AIDS HIV Treat."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/jmv.25732","article-title":"Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China","volume":"92","author":"Zhu","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"104826","DOI":"10.1016\/j.phrs.2020.104826","article-title":"Darunavir does not prevent SARS-CoV-2 infection in HIV patients","volume":"157","author":"Riva","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e314","DOI":"10.1016\/S2352-3018(20)30111-9","article-title":"COVID-19 in patients with HIV: Clinical case series","volume":"7","author":"Blanco","year":"2020","journal-title":"Lancet HIV"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"JC3","DOI":"10.7326\/ACPJ202101190-003","article-title":"In severe COVID-19, adding lopinavir\u2013ritonavir to usual care did not improve mortality at 28 days","volume":"174","author":"Singh","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Mellor, M.M., Bast, A.C., Jones, N.R., Roberts, N.W., Ord\u00f3\u00f1ez-Mena, J.M., Reith, A.J., Butler, C.C., Matthews, P.C., and Dorward, J. (2021). Risk of adverse COVID-19 outcomes for people living with HIV. AIDS, F1\u2013F10.","DOI":"10.1101\/2020.09.22.20199661"},{"key":"ref_20","unstructured":"Patel, R.H., Acharya, A., Chand, H.S., Mohan, M., and Byrareddy, S.N. (2021). HIV and SARS-CoV-2 Co-infection: A Systematic Review of the Literature and Challenges. AIDS Res. Hum. Retrovir."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e044618","DOI":"10.1136\/bmjopen-2020-044618","article-title":"Risk factors for COVID-19 infection, disease severity and related deaths in Africa: A systematic review","volume":"11","author":"Gesesew","year":"2021","journal-title":"BMJ Open"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/COH.0000000000000659","article-title":"The interplay between HIV and COVID-19: Summary of the data and responses to date","volume":"16","author":"Brown","year":"2021","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2020.06.002","article-title":"Letter to the Editor on \u201cBonaf\u00e8 M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri, F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Rev\u201d","volume":"54","author":"Biasiotto","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hiv.12935","article-title":"What do the changing patterns of comorbidity burden in people living with HIV mean for long-term management? Perspectives from European HIV cohorts","volume":"21","author":"Monforte","year":"2020","journal-title":"HIV Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11904-019-00464-3","article-title":"Aging with HIV","volume":"16","author":"Guaraldi","year":"2019","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1016\/S2352-3018(20)30139-9","article-title":"COVID-19 in patients with HIV","volume":"7","author":"Jones","year":"2020","journal-title":"Lancet HIV"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Byrd, K.M., Beckwith, C.G., Garland, J.M., Johnson, J.E., Aung, S., Cu-Uvin, S., Farmakiotis, D., Flanigan, T., Gillani, F.S., and Macias-Gil, R. (2020). SARS-CoV-2 and HIV coinfection: Clinical experience from Rhode Island, United States. J. Int. AIDS Soc., 23.","DOI":"10.1002\/jia2.25573"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e524","DOI":"10.1016\/S2352-3018(20)30163-6","article-title":"COVID-19 in people with HIV","volume":"7","author":"Xu","year":"2020","journal-title":"Lancet HIV"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1002\/jmv.26006","article-title":"Recovery from the coronavirus disease-2019 (COVID-19) in two patients with coexisted (HIV) infection","volume":"92","author":"Wu","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e554","DOI":"10.1016\/S2352-3018(20)30164-8","article-title":"Description of COVID-19 in HIV-infected individuals: A single-centre, prospective cohort","volume":"7","author":"Vizcarra","year":"2020","journal-title":"Lancet HIV"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s15010-020-01438-z","article-title":"COVID-19 in people living with human immunodeficiency virus: A case series of 33 patients","volume":"48","author":"Spinner","year":"2020","journal-title":"Infection"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1097\/QAI.0000000000002411","article-title":"COVID-19 Pneumonia in Patients with HIV: A Case Series","volume":"85","author":"Okoh","year":"2020","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1093\/cid\/ciaa579","article-title":"Clinical Features and Outcomes of Patients with Human Immunodeficiency Virus With COVID-19","volume":"71","author":"Gervasoni","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/aje\/kwaa158","article-title":"HIV and COVID-19: Intersecting Epidemics with Many Unknowns","volume":"190","author":"Lesko","year":"2021","journal-title":"Am. J. Epidemiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/QAI.0000000000002423","article-title":"Outcomes among HIV-Positive Patients Hospitalized with COVID-19","volume":"85","author":"Carlucci","year":"2020","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10461-020-02983-2","article-title":"COVID-19 among People Living with HIV: A Systematic Review","volume":"25","author":"Mirzaei","year":"2021","journal-title":"AIDS Behav."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/17476348.2021.1836965","article-title":"Clinical characteristics of COVID-19 patients with HIV coinfection in Wuhan, China","volume":"15","author":"Yang","year":"2021","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Lee, K., Yap, S., Ngeow, Y., and Lye, M. (2021). COVID-19 in People Living with HIV: A Systematic Review and Meta-Analysis. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18073554"},{"key":"ref_39","first-page":"1","article-title":"COVID-19 infection in a HIV positive health care worker: First case report from a tertiary care hospital of North India","volume":"2021","author":"Mohindra","year":"2021","journal-title":"VirusDisease"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s15010-020-01492-7","article-title":"COVID-19 in patients with HIV-1 infection: A single-centre experience in northern Italy","volume":"49","author":"Calza","year":"2021","journal-title":"Infection"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/hiv.13037","article-title":"Immune deficiency is a risk factor for severe COVID-19 in people living with HIV","volume":"22","author":"Hoffmann","year":"2021","journal-title":"HIV Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/COH.0000000000000654","article-title":"The first 6 months of HIV-SARS-CoV-2 coinfection: Outcomes for 6947 individuals","volume":"16","author":"Johnston","year":"2021","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/jmv.25782","article-title":"SARS-CoV-2 and HIV","volume":"92","author":"Joob","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAI.0000000000002424","article-title":"Coinfection with HIV and SARS-CoV-2 in Wuhan, China: A 12-Person Case Series","volume":"85","author":"Hu","year":"2020","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1089\/apc.2020.0103","article-title":"A Case Series of Five People Living with HIV Hospitalized with COVID-19 in Chicago, Illinois","volume":"34","author":"Ridgway","year":"2020","journal-title":"AIDS Patient Care STDs"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1002\/jmv.25879","article-title":"Computed tomography imaging of an HIV-infected patient with coronavirus disease 2019","volume":"92","author":"Chen","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1089\/apc.2020.29005.com","article-title":"Why Aren\u2019t People Living with HIV at Higher Risk for Developing Severe Coronavirus Disease 2019 (COVID-19)?","volume":"34","author":"Laurence","year":"2020","journal-title":"AIDS Patient Care STDs"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/AAC.37.2.332","article-title":"Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: Potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine","volume":"37","author":"Balzarini","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1126\/science.270.5239.1197","article-title":"Prevention of SIV Infection in Macaques by (R)-9-(2-Phosphonylmethoxypropyl)adenine","volume":"270","author":"Follis","year":"1995","journal-title":"Science"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"117592","DOI":"10.1016\/j.lfs.2020.117592","article-title":"Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study","volume":"253","author":"Elfiky","year":"2020","journal-title":"Life Sci."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Edited Li, G., Yue, T., Zhang, P., Gu, W., Gao, L.-J., and Tan, L. (2021). Drug Discovery of Nucleos(t)ide Antiviral Agents: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Birthday. Molecules, 26.","DOI":"10.3390\/molecules26040923"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Wassner, C., Bradley, N., and Lee, Y. (2020). A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide. J. Int. Assoc. Provid. AIDS Care (JIAPAC), 19.","DOI":"10.1177\/2325958220919231"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/14656566.2020.1713096","article-title":"Evaluating emtricitabine + rilpivirine + tenofovir alafenamide in combination for the treatment of HIV-infection","volume":"21","author":"Mu","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"100028","DOI":"10.1016\/j.jve.2021.100028","article-title":"The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV","volume":"7","author":"Waters","year":"2021","journal-title":"J. Virus Erad."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1177\/1060028020933772","article-title":"Doing More with Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Na\u00efve Adults with HIV-1 Infection","volume":"54","author":"Santevecchi","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"ref_56","first-page":"8","article-title":"CROI 2019: Advances in HIV prevention and plans to end the epidemic","volume":"27","author":"Buchbinder","year":"2019","journal-title":"Top. Antivir. Med."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Biello, K.B., Mimiaga, M.J., Valente, P.K., Saxena, N., and Bazzi, A.R. (2021). The Past, Present, and Future of PrEP implementation among People Who Use Drugs. Curr. HIV\/AIDS Rep.","DOI":"10.1007\/s11904-021-00556-z"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2147\/HIV.S216024","article-title":"Pre-Exposure Prophylaxis (PrEP) in the Prevention of HIV: Strategies, Target Populations and Upcoming Treatments","volume":"12","author":"Slugocki","year":"2020","journal-title":"HIV\/AIDS Res. Palliat. Care"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1097\/QAI.0000000000002169","article-title":"PrEP 1.0 and Beyond: Optimizing a Biobehavioral Intervention","volume":"82","author":"Mayer","year":"2019","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jama.2018.1917","article-title":"HIV Preexposure Prophylaxis","volume":"319","author":"Riddell","year":"2018","journal-title":"JAMA"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1097\/QAD.0000000000001145","article-title":"Effectiveness and safety of oral HIV preexposure prophylaxis for all populations","volume":"30","author":"Fonner","year":"2016","journal-title":"AIDS"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Sun, S., Yang, Q., Sheng, Y., Fu, Y., Sun, C., and Deng, C. (2020). Investigational drugs with dual activity against HBV and HIV (Review). Exp. Ther. Med., 21.","DOI":"10.3892\/etm.2020.9467"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Roade, L., Riveiro-Barciela, M., Esteban, R., and Buti, M. (2021). Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B. Ther. Adv. Infect. Dis., 8.","DOI":"10.1177\/2049936120985954"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Hall, S., Howell, J., Visvanathan, K., and Thompson, A. (2020). The Yin and the Yang of Treatment for Chronic Hepatitis B\u2014When to Start, When to Stop Nucleos(t)ide Analogue Therapy. Viruses, 12.","DOI":"10.3390\/v12090934"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/infdis\/jiz045","article-title":"Tenofovir Gel for Prevention of Herpes Simplex Virus Type 2 Acquisition: Findings from the VOICE Trial","volume":"219","author":"Marrazzo","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Chaix, M.-L., Charreau, I., Pintado, C., Delaugerre, C., Mahjoub, N., Cotte, L., Capitant, C., Raffi, F., Cua, E., and Pialoux, G. (2018). Effect of On-Demand Oral Pre-exposure Prophylaxis with Tenofovir\/Emtricitabine on Herpes Simplex Virus-1\/2 Incidence among Men Who Have Sex with Men: A Substudy of the ANRS IPERGAY Trial. Open Forum. Infect. Dis., 5.","DOI":"10.1093\/ofid\/ofy295"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/infdis\/jix605","article-title":"The Anti\u2013Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase","volume":"217","author":"Andrei","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/infdis\/jix029","article-title":"Herpes Simplex Virus Type 2 Acquisition among HIV-1\u2013Infected Adults Treated with Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results from the ACTG A5175 PEARLS Study","volume":"215","author":"Celum","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40265-019-01108-x","article-title":"Drug Resistance during HIV Pre-Exposure Prophylaxis","volume":"79","author":"Gibas","year":"2019","journal-title":"Drugs"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/jama.2018.3795","article-title":"Chronic Hepatitis B Infection","volume":"319","author":"Tang","year":"2018","journal-title":"JAMA"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jhep.2019.02.006","article-title":"Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients","volume":"70","author":"Park","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"DeJong, C., Spinelli, M.A., Okochi, H., and Gandhi, M. (2021). Tenofovir-based PrEP for COVID-19. AIDS.","DOI":"10.1097\/QAD.0000000000002877"},{"key":"ref_73","first-page":"1","article-title":"In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV","volume":"10","author":"Gbayo","year":"2021","journal-title":"Netw. Model. Anal. Health Inform. Bioinform."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"106564","DOI":"10.1016\/j.bpc.2021.106564","article-title":"Evaluation of potential anti-RNA-dependent RNA polymerase (RdRP) drugs against the newly emerged model of COVID-19 RdRP using computational methods","volume":"272","author":"Poustforoosh","year":"2021","journal-title":"Biophys. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ijbiomac.2020.12.223","article-title":"Denovo designing, retro-combinatorial synthesis, and molecular dynamics analysis identify novel antiviral VTRM1.1 against RNA-dependent RNA polymerase of SARS CoV2 virus","volume":"171","author":"Tiwari","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_76","first-page":"1","article-title":"SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: An in silico perspective","volume":"2020","author":"ElFiky","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"100539","DOI":"10.1016\/j.imu.2021.100539","article-title":"Evaluation of drug repositioning by molecular docking of pharmaceutical resources available in the Brazilian healthcare system against SARS-CoV-2","volume":"23","author":"Perin","year":"2021","journal-title":"Inform. Med. Unlocked"},{"key":"ref_78","first-page":"1","article-title":"Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection","volume":"2021","author":"Copertino","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e06435","DOI":"10.1016\/j.heliyon.2021.e06435","article-title":"Structural analogues of existing anti-viral drugs inhibit SARS-CoV-2 RNA dependent RNA polymerase: A computational hierarchical investigation","volume":"7","author":"Hasan","year":"2021","journal-title":"Heliyon"},{"key":"ref_80","first-page":"2435","article-title":"Early combination treatment with existing HIV antivirals: An effective treatment for COVID-19?","volume":"25","author":"Dallocchio","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/jac\/dkaa444","article-title":"Key genetic elements, single and in clusters, underlying geographically dependent SARS-CoV-2 genetic adaptation and their impact on binding affinity for drugs and immune control","volume":"76","author":"Salpini","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"458","DOI":"10.7555\/JBR.34.20200044","article-title":"Identification of therapeutic drugs against COVID-19 through computational investigation on drug repurposing and structural modification","volume":"34","author":"Yun","year":"2020","journal-title":"J. Biomed. Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"173720","DOI":"10.1016\/j.ejphar.2020.173720","article-title":"Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19","volume":"890","author":"Toor","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"117652","DOI":"10.1016\/j.lfs.2020.117652","article-title":"In silico studies on therapeutic agents for COVID-19: Drug repurposing approach","volume":"252","author":"Shah","year":"2020","journal-title":"Life Sci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"100531","DOI":"10.1016\/j.imu.2021.100531","article-title":"Identification of potential antivirals against SARS-CoV-2 using virtual screening method","volume":"23","author":"Banik","year":"2021","journal-title":"Inform. Med. Unlocked"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/bib\/bbaa260","article-title":"MCCS: A novel recognition pattern-based method for fast track discovery of anti-SARS-CoV-2 drugs","volume":"22","author":"Feng","year":"2021","journal-title":"Brief. Bioinform."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"104786","DOI":"10.1016\/j.antiviral.2020.104786","article-title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro","volume":"178","author":"Choy","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e01652-20","DOI":"10.1128\/AAC.01652-20","article-title":"Repurposing Nucleoside Analogs for Human Coronaviruses","volume":"65","author":"Zandi","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_89","first-page":"1552","article-title":"Tenofovir Disoproxil Fumarate: New Chemical Developments and Encouraging in vitro Biological Results for SARS-CoV-2","volume":"31","author":"Clososki","year":"2020","journal-title":"J. Braz. Chem. Soc."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1038\/s41467-020-19055-7","article-title":"A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19","volume":"11","author":"Xie","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Veras, F.P., Pontelli, M.C., Silva, C.M., Toller-Kawahisa, J.E., De Lima, M., Nascimento, D.C., Schneider, A.H., Caetit\u00e9, D., Tavares, L.A., and Paiva, I.M. (2020). SARS-CoV-2\u2013triggered neutrophil extracellular traps mediate COVID-19 pathology. J. Exp. Med., 217.","DOI":"10.1084\/jem.20201129"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1021\/acs.jproteome.0c00392","article-title":"Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19","volume":"19","author":"Chien","year":"2020","journal-title":"J. Proteome Res."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Park, S.-J., Yu, K.-M., Kim, Y.-I., Kim, S.-M., Kim, E.-H., Kim, S.-G., Casel, M.A.B., Rollon, R., Jang, S.-G., and Lee, M.-H. (2020). Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets. mBio, 11.","DOI":"10.1128\/mBio.01114-20"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Boulle, A., Davies, M.-A., Hussey, H., Ismail, M., Morden, E., Vundle, Z., Zweigenthal, V., Mahomed, H., Paleker, M., and Pienaar, D. (2020). Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa. Clin. Infect. Dis.","DOI":"10.1101\/2020.07.02.20145185"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"536","DOI":"10.7326\/M20-3689","article-title":"Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy","volume":"173","author":"Polo","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1097\/EDE.0000000000001235","article-title":"Antiretrovirals and Risk of COVID-19 Diagnosis and Hospitalization in HIV-Positive Persons","volume":"31","author":"Polo","year":"2020","journal-title":"Epidemiology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/QAI.0b013e3182185276","article-title":"Tenofovir Selectively Regulates Production of Inflammatory Cytokines and Shifts the IL-12\/IL-10 Balance in Human Primary Cells","volume":"57","author":"Melchjorsen","year":"2011","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/QAI.0000000000000529","article-title":"Reduced Immune Activation during Tenofovir\u2013Emtricitabine Therapy in HIV-Negative Individuals","volume":"68","author":"Meditz","year":"2015","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"ofaa455","DOI":"10.1093\/ofid\/ofaa455","article-title":"Preventive Efficacy of Tenofovir\/Emtricitabine against Severe Acute Respiratory Syndrome Coronavirus 2 among Pre-Exposure Prophylaxis Users","volume":"7","author":"Ayerdi","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_100","unstructured":"(2021, April 12). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04519125."},{"key":"ref_101","unstructured":"(2021, April 12). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04405271."},{"key":"ref_102","unstructured":"(2021, April 12). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04575545."},{"key":"ref_103","unstructured":"(2021, April 12). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04712357."},{"key":"ref_104","unstructured":"(2021, April 12). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04685512."},{"key":"ref_105","unstructured":"(2021, April 12). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04359095."},{"key":"ref_106","unstructured":"(2021, April 12). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04334928."},{"key":"ref_107","unstructured":"(2021, April 12). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04812496."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"104904","DOI":"10.1016\/j.phrs.2020.104904","article-title":"The possible mechanisms of action of 4-aminoquinolines (chloroquine\/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?","volume":"158","author":"Roldan","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_109","first-page":"93","article-title":"Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Eze","year":"2021","journal-title":"Am. J. Cardiovasc. Dis."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2165\/00003088-200443090-00003","article-title":"Tenofovir Disoproxil Fumarate","volume":"43","author":"Kearney","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Geraghty, R., Aliota, M., and Bonnac, L. (2021). Broad-Spectrum Antiviral Strategies and Nucleoside Analogues. Viruses, 13.","DOI":"10.3390\/v13040667"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"590154","DOI":"10.3389\/fphar.2020.590154","article-title":"A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review","volume":"11","author":"Dash","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/jcph.1788","article-title":"Antiretrovirals for Prophylaxis against COVID-19: A Comprehensive Literature Review","volume":"61","author":"Alavian","year":"2020","journal-title":"J. Clin. Pharmacol."}],"updated-by":[{"DOI":"10.3390\/ph14080827","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000}}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/14\/5\/454\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T22:34:52Z","timestamp":1754260492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/14\/5\/454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,11]]},"references-count":113,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["ph14050454"],"URL":"https:\/\/doi.org\/10.3390\/ph14050454","relation":{"correction":[{"id-type":"doi","id":"10.3390\/ph14080827","asserted-by":"object"}]},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,11]]}}}